Market Closed -
Toronto S.E.
04:50:53 2024-07-05 pm EDT
|
5-day change
|
1st Jan Change
|
2.7
CAD
|
0.00%
|
|
-1.10%
|
+145.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
118.5
|
91.34
|
142
|
43.96
|
71.77
|
184.6
|
-
|
-
|
Enterprise Value (EV)
1 |
111.8
|
77.47
|
142
|
43.96
|
36.84
|
165.8
|
171
|
184.6
|
P/E ratio
|
-8.64
x
|
-4.03
x
|
-3.19
x
|
-1.41
x
|
-2.5
x
|
-5.87
x
|
-6.39
x
|
-6.51
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
1,803
x
|
-
|
-
|
-
|
-
|
50.2
x
|
EV / Revenue
|
-
|
-
|
1,803
x
|
-
|
-
|
-
|
-
|
50.2
x
|
EV / EBITDA
|
-10.4
x
|
-4.38
x
|
-4.74
x
|
-1.07
x
|
-1.25
x
|
-5.93
x
|
-7.46
x
|
-6.21
x
|
EV / FCF
|
-9.47
x
|
-8.4
x
|
-6.03
x
|
-
|
-1.46
x
|
-9.5
x
|
-9.74
x
|
-6.05
x
|
FCF Yield
|
-10.6%
|
-11.9%
|
-16.6%
|
-
|
-68.5%
|
-10.5%
|
-10.3%
|
-16.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
2.55
x
|
9.12
x
|
15.2
x
|
-
|
Nbr of stocks (in thousands)
|
25,878
|
32,856
|
60,954
|
63,703
|
65,247
|
68,373
|
-
|
-
|
Reference price
2 |
4.580
|
2.780
|
2.330
|
0.6900
|
1.100
|
2.700
|
2.700
|
2.700
|
Announcement Date
|
3/26/20
|
3/31/21
|
3/23/22
|
3/28/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.0788
|
-
|
-
|
-
|
-
|
3.675
|
EBITDA
1 |
-10.71
|
-17.7
|
-29.95
|
-41.12
|
-29.54
|
-27.96
|
-22.93
|
-29.74
|
EBIT
1 |
-13.98
|
-20.53
|
-38.66
|
-41.34
|
-29.79
|
-32.29
|
-33.58
|
-33.83
|
Operating Margin
|
-
|
-
|
-49,091.92%
|
-
|
-
|
-
|
-
|
-920.67%
|
Earnings before Tax (EBT)
1 |
-13.68
|
-20.64
|
-31.64
|
-30.93
|
-28.13
|
-32.31
|
-33.96
|
-36
|
Net income
1 |
-13.68
|
-20.64
|
-31.64
|
-30.93
|
-28.13
|
-32.31
|
-33.96
|
-36
|
Net margin
|
-
|
-
|
-40,170.44%
|
-
|
-
|
-
|
-
|
-979.59%
|
EPS
2 |
-0.5300
|
-0.6900
|
-0.7300
|
-0.4900
|
-0.4400
|
-0.4600
|
-0.4225
|
-0.4150
|
Free Cash Flow
1 |
-11.8
|
-9.226
|
-23.56
|
-
|
-25.24
|
-17.45
|
-17.55
|
-30.5
|
FCF margin
|
-
|
-
|
-29,918.36%
|
-
|
-
|
-
|
-
|
-829.93%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/31/21
|
3/23/22
|
3/28/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-8.453
|
-
|
-9.178
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.1
|
-9.788
|
-9.232
|
-13.22
|
-9.095
|
-7.786
|
-6.315
|
-7.656
|
-8.029
|
-8.405
|
-8.667
|
-8.8
|
-8.933
|
-9.3
|
-9.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.257
|
-8.954
|
-6.489
|
-7.972
|
-7.515
|
-7.089
|
-7.472
|
-5.93
|
-7.637
|
-9.18
|
-8.6
|
-8.733
|
-8.867
|
-9.3
|
-9.6
|
Net income
1 |
-6.257
|
-8.954
|
-6.489
|
-7.972
|
-7.515
|
-7.089
|
-7.472
|
-5.93
|
-7.637
|
-9.18
|
-8.6
|
-8.733
|
-8.867
|
-9.3
|
-9.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1100
|
-0.1400
|
-0.1000
|
-0.1300
|
-0.1100
|
-0.1100
|
-0.1200
|
-0.0900
|
-0.1200
|
-0.1400
|
-0.1267
|
-0.1233
|
-0.1133
|
-0.1200
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
5/16/22
|
8/10/22
|
11/10/22
|
3/28/23
|
5/15/23
|
8/10/23
|
11/14/23
|
4/1/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
6.77
|
13.9
|
-
|
-
|
34.9
|
18.8
|
13.6
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-11.8
|
-9.23
|
-23.6
|
-
|
-25.2
|
-17.4
|
-17.6
|
-30.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
0.4300
|
0.3000
|
0.1800
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.01
|
-
|
0.06
|
0.08
|
0.11
|
-
|
Capex / Sales
|
-
|
-
|
16.4%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/31/21
|
3/23/22
|
3/28/23
|
4/1/24
|
-
|
-
|
-
|
Average target price
11
CAD Spread / Average Target +307.41% Consensus |
1st Jan change
|
Capi.
|
---|
| +145.45% | 135M | | +18.97% | 45.34B | | +41.98% | 40.42B | | -10.06% | 37.92B | | +31.15% | 31.75B | | -7.79% | 27.71B | | +13.32% | 26.52B | | +43.05% | 13.96B | | +31.28% | 12.44B | | -7.41% | 11.26B |
Other Biotechnology & Medical Research
|